

September 9, 2015



# Actinium to Participate at the FBR Second Annual Healthcare Conference

## Boston Area Institutional Investors to Meet Management

NEW YORK, NY -- (Marketwired) -- 09/09/15 --

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company will participate at FBR Second Annual Healthcare Conference on Wednesday, September 9, 2015 at the Four Seasons Hotel in Boston.

Members of the investment community who are interested in meeting with Actinium's senior management team in a one-on-one setting should contact their FBR representative, or otherwise contact Actinium Investor Relations at [investorrelations@actiniumpharma.com](mailto:investorrelations@actiniumpharma.com).

### ***About FBR Second Annual Healthcare Conference***

FBR Second Annual Healthcare Conference brings together investors and senior management for a day of 1on1s featuring more than 60 companies across the biotech, biopharma, healthcare IT, managed care, pharmaceutical, and clinical lab sectors. Should you require further information, please contact the FBR Conference and 1on1 Desk ([1on1@fbr.com](mailto:1on1@fbr.com)).

### ***About Iomab-B™***

Iomab-B™ is being developed to prepare patients for hematopoietic stem cell transplantation (HSCT) and will enter a single, pivotal Phase 3 clinical study in relapsed/refractory AML. Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine- 131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML).

### ***About Actimab-A***

Actimab-A is a radiolabeled antibody being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase 1/2 clinical trial. Based on Actinium's alpha-particle immunotherapy (APIT) platform, Actimab-A consists of the CD33 antibody lintuzumab linked to the actinium-225 payload. Actimab-A has attracted support from leading

experts at the prestigious and high-volume cancer treatment hospitals due to the potential of its safety and efficacy profile, as well as its potential potency, specificity and ease of use. Clinical trials are being conducted at world-class cancer institutions such as Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Johns Hopkins Medicine, Columbia University Medical Center, University of Pennsylvania Health System, Fred Hutchinson Cancer Research Center, and the Texas Oncology- Baylor Charles A. Sammons Cancer Center. Actimab candidates are in early development for other cancers.

### ***About Actinium Pharmaceuticals***

Actinium Pharmaceuticals, Inc. ([www.actiniumpharma.com](http://www.actiniumpharma.com)) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

### ***Forward-Looking Statement for Actinium Pharmaceuticals, Inc.***

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

David Gould, MD  
SVP, Finance and Corporate Development  
Actinium Pharmaceuticals, Inc.  
[dgould@actiniumpharma.com](mailto:dgould@actiniumpharma.com)

Source: Actinium Pharmaceuticals